This inventor holds 2 USPTO granted patents and 1 published patent application. Top assignee: Glaxosmithkline Intellectual Property Development Limited. Active years: 2018-2021.
Company Filing History:
Years Active: 2018-2021
Title: Innovations by Chong Ding in Neurological Treatments
Introduction
Chong Ding is an accomplished inventor based in Shanghai, China. He has made significant contributions to the field of neurological treatments through his innovative research and development. With a total of 2 patents, Ding's work focuses on the use of TrkB binding agonists for treating various neurological disorders.
Latest Patents
Chong Ding's latest patents include a groundbreaking invention related to TrkB binding agonists. This invention pertains to the use of these agonists in the treatment of neurological disorders and other related conditions. The patent details specific TrkB binding agonists that comprise CDRs, variable regions, heavy and light chains, along with variant sequences thereof. This innovative approach aims to provide new therapeutic options for patients suffering from neurological issues.
Career Highlights
Chong Ding is currently associated with GlaxoSmithKline Intellectual Property Development Limited, where he continues to advance his research in the field of neurological treatments. His work has garnered attention for its potential impact on improving patient outcomes in various neurological disorders.
Collaborations
Chong Ding collaborates with notable professionals in his field, including Tejinder Kaur Bhinder and Xu Feng. These collaborations enhance the research and development process, leading to more effective solutions for neurological challenges.
Conclusion
Chong Ding's innovative contributions to the field of neurological treatments through his patents highlight his dedication to improving healthcare. His work with TrkB binding agonists represents a significant advancement in the treatment of neurological disorders.